Statement: Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.
Primary_evidence: INTERVENTION 1:    Cabozantinib   Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
Secondary_evidence: INTERVENTION 1:    Phase I: Cyclophosphamide, Doxil, Trastuzumab   Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.   pegylated liposomal doxorubicin hydrochloride: Given IV   cyclophosphamide: Given orally   trastuzumab: Given IV